These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33030198)

  • 21. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
    Mdluli K; Ma Z
    Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition.
    Reddy KI; Srihari K; Renuka J; Sree KS; Chuppala A; Jeankumar VU; Sridevi JP; Babu KS; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Dec; 22(23):6552-6563. PubMed ID: 25456076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
    Sriram D; Aubry A; Yogeeswari P; Fisher LM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
    Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
    Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of novel quinoline-aminopiperidine derivatives as
    Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
    J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads.
    Jeankumar VU; Renuka J; Pulla VK; Soni V; Sridevi JP; Suryadevara P; Shravan M; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Int J Antimicrob Agents; 2014 Mar; 43(3):269-78. PubMed ID: 24434114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.
    Gibson EG; Blower TR; Cacho M; Bax B; Berger JM; Osheroff N
    ACS Infect Dis; 2018 Aug; 4(8):1211-1222. PubMed ID: 29746087
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Quimque MTJ; Go AD; Lim JAK; Vidar WS; Macabeo APG
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioisosteric Design Identifies Inhibitors of
    Kamsri B; Pakamwong B; Thongdee P; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Goudar KE; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2023 May; 63(9):2707-2718. PubMed ID: 37074047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
    Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
    J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extending the N-linked aminopiperidine class to the mycobacterial gyrase domain: pharmacophore mapping from known antibacterial leads.
    Bobesh KA; Renuka J; Jeankumar VU; Shruti SK; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 85():593-604. PubMed ID: 25127151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
    Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
    Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.
    Salve PS; Alegaon SG; Sriram D
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1859-1866. PubMed ID: 28274627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.
    Jeankumar VU; Reshma RS; Vats R; Janupally R; Saxena S; Yogeeswari P; Sriram D
    Eur J Med Chem; 2016 Oct; 122():216-231. PubMed ID: 27371925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
    Govender P; Müller R; Singh K; Reddy V; Eyermann CJ; Fienberg S; Ghorpade SR; Koekemoer L; Myrick A; Schnappinger D; Engelhart C; Meshanni J; Byl JAW; Osheroff N; Singh V; Chibale K; Basarab GS
    J Med Chem; 2022 May; 65(9):6903-6925. PubMed ID: 35500229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
    Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
    J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
    Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY
    Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
    Medapi B; Renuka J; Saxena S; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 May; 23(9):2062-78. PubMed ID: 25801151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.